Atlas Trials

Recurrent Hematologic Malignancy

9 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Hematologic Malignancy

RecordFirmDate
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer (NCT05058339)M.D. Anderson Cancer Center2021-04-27
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105)City of Hope Medical Center2020-11-18
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633)Rutgers, The State University of New Jersey2020-10-26
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606)City of Hope Medical Center2020-10-20
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524)OHSU Knight Cancer Institute2020-04-01
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (NCT02333162)University of Chicago2014-12-05
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509)National Cancer Institute (NCI)2013-05-16

Track Recurrent Hematologic Malignancy automatically

Every clearance here is in the API, with alerts when new ones post.